- Corporate Officers - K
- Kim Helen Susan
Insider Trading History of Kim Helen Susan
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Kim Helen Susan since 2016.
This trader's CIK number is 1422772.
At the time of last reporting, Kim Helen Susan was the Officer of Aktis Oncology, Inc.. (stock ticker symbol AKTS).
Also see all insider trading activities at Aktis Oncology, Inc..
Note that in the past
Kim Helen Susan also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Applied Molecular Transport Inc. (AMTI) by Kim Helen Susan
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2021 | AMTI | 0 | $0 | 225,000 | $9,720,349 | 0 | $0 |
| 2020 | AMTI | 0 | $0 | 0 | $0 | 800,000 | $16,000 |
Yearly summary of insider trading at Kite Pharma, Inc. (KITE) by Kim Helen Susan
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2017 | KITE | 0 | $0 | 173,520 | $17,777,590 | 170,349 | $9,076,093 |
| 2016 | KITE | 0 | $0 | 36,836 | $2,211,445 | 35,900 | $1,846,337 |
Yearly summary of insider trading at Aktis Oncology, Inc. (AKTS) by Kim Helen Susan
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2026 | AKTS | 835,000 | $15,030,000 | 0 | $0 | 0 | $0 |
Insider trading activities at 3 companies by Kim Helen Susan:
1. Applied Molecular Transport Inc. (AMTI)
2. Kite Pharma, Inc. (KITE)
3. Aktis Oncology, Inc. (AKTS)
Table 1. Insider trading of Applied Molecular Transport Inc. (AMTI) by Kim Helen Susan
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2021-08-26 | AMTI | Sale | 14,063 | 30.57 | 429,835 |
| 2021-08-27 | AMTI | Sale | 951 | 31.10 | 29,578 |
| 2021-08-24 | AMTI | Sale | 508 | 30.04 | 15,257 |
| 2021-08-25 | AMTI | Sale | 9,478 | 30.08 | 285,079 |
| 2021-07-02 | AMTI | Sale | 200,000 | 44.80 | 8,960,600 |
| 2020-07-02 | AMTI | Option Ex | 800,000 | .02 | 16,000 |
Table 2. Insider trading of Kite Pharma, Inc. (KITE) by Kim Helen Susan
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2017-09-25 | KITE | Sale | 3,171 | 179.66 | 569,714 |
| 2017-08-10 | KITE | Option Ex | 6,251 | 52.66 | 329,208 |
| 2017-08-10 | KITE | Sale | 6,251 | 120.09 | 750,682 |
| 2017-08-08 | KITE | Option Ex | 79,949 | 53.90 | 4,309,251 |
| 2017-08-08 | KITE | Sale | 79,949 | 118.77 | 9,495,382 |
| 2017-07-31 | KITE | Option Ex | 26,649 | 52.66 | 1,403,469 |
| 2017-07-31 | KITE | Sale | 26,649 | 110.16 | 2,935,653 |
| 2017-06-01 | KITE | Option Ex | 2,400 | 51.43 | 123,432 |
| 2017-06-01 | KITE | Sale | 2,400 | 72.45 | 173,880 |
| 2017-05-01 | KITE | Option Ex | 2,400 | 53.90 | 129,360 |
| 2017-05-01 | KITE | Sale | 2,400 | 82.12 | 197,088 |
| 2017-04-03 | KITE | Sale | 2,400 | 81.80 | 196,320 |
| 2017-04-03 | KITE | Option Ex | 2,400 | 53.90 | 129,360 |
| 2017-03-01 | KITE | Sale | 2,400 | 74.27 | 178,248 |
| 2017-02-28 | KITE | Sale | 47,900 | 68.49 | 3,280,623 |
| 2017-03-01 | KITE | Option Ex | 2,400 | 53.90 | 129,360 |
| 2017-02-28 | KITE | Option Ex | 47,900 | 52.66 | 2,522,653 |
| 2016-12-20 | KITE | Sale | 936 | 50.86 | 47,604 |
| 2016-08-12 | KITE | Sale | 33,500 | 60.08 | 2,012,613 |
| 2016-08-15 | KITE | Option Ex | 2,400 | 51.43 | 123,432 |
| 2016-08-15 | KITE | Sale | 2,400 | 63.01 | 151,228 |
| 2016-08-12 | KITE | Option Ex | 33,500 | 51.43 | 1,722,905 |
Table 3. Insider trading of Aktis Oncology, Inc. (AKTS) by Kim Helen Susan
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2026-01-12 | AKTS | Buy | 835,000 | 18.00 | 15,030,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Kim Helen Susan
(Officer of Aktis Oncology, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.